#38: A Molecular Dynamics Study of Electrostatic and Hydrophobic Interactions between Transthyretin and Model Drug Molecules — Presentation Detail — Celebration of Scholars

Instructions

Student presentations must have a faculty sponsor.

Abstracts must include a title and a description of the research, scholarship, or creative work. The description should be 150-225 words in length and constructed in a format or style appropriate for the presenter’s discipline.

The following points should be addressed within the selected format or style for the abstract:

A clear statement of the problem or question you pursued, or the scholarly goal or creative theme achieved in your work.
A brief comment about the significance or uniqueness of the work.
A clear description of the methods used to achieve the purpose or goals for the work.
A statement of the conclusions, results, outcomes, or recommendations, or if the work is still in progress, the results you expect to report at the event.

Presenter photographs should be head and shoulder shots comparable to passport photos.

Additional Information

More information is available at carthage.edu/celebration-scholars/. The following are members of the Research, Scholarship, and Creativity Committee who are eager to listen to ideas and answer questions:

Jun Wang
Kim Instenes
John Kirk
Nora Nickels
Andrew Pustina
James Ripley

#38: A Molecular Dynamics Study of Electrostatic and Hydrophobic Interactions between Transthyretin and Model Drug Molecules

Name: Lucus Schneider
Major: Neuroscience and Chemistry
Hometown: Avoca, Wisconsin
Faculty Sponsor:
Other Sponsors:
Type of research: Independent research
Funding: NSF

Abstract

Transthyretin (TTR) is protein produced in liver that carries the hormone thyroxine and retinol through the blood and spinal fluid. Familial Amyloidal Cardiomyopathy is a genetic disorder causing TTR to misfold and form into amyloid plaques on the muscle walls of the heart. One instance of misfolding involves a point mutation involving Valine-122 to Isoleucine, which is present in 3 % of African Americans. There are few FDA-approved drugs to treat FAC; however, recent studies of drug interactions with TTR utilizing molecular dynamics simulations have been done. Some of these studies investigate the interactions between the drug molecule TKS-14 and TTR. In those simulations, TTR residue Lys-15 was determined to be and important residue for hydrogen bonding between TTR and TKS-14. This project investigated further the importance of this interaction and any hydrophobic interactions that occur between TKS-14 and TTR. The latter studies were done by modifying the center pyrazole ring in TKS-14. When Lys-15 was mutated to leucine, the TKS-14 molecule remained in the TTR binding pocket. However, the ligand-TTR binding energy was reduced. These results will be presented along with studies mapping the TKS_14-TTR intermolecular interactions.

Poster file